Top

Published in:

01-07-2016 | Crystal Arthritis (MH Pillinger and SK Samuels, Section Editors)

Gout Classification Criteria: Update and Implications

Authors: Ana Beatriz Vargas-Santos, William J. Taylor, Tuhina Neogi

Published in: Current Rheumatology Reports | Issue 7/2016

Abstract

Gout is the most common inflammatory arthritis, with a rising prevalence and incidence worldwide. There has been a resurgence in gout research, fueled, in part, by a number of advances in pharmacologic therapy for gout. The conduct of clinical trials and other observational research in gout requires a standardized and validated means of assembling well-defined groups of patients with gout for such research purposes. Recently, an international collaborative effort that involved a data-driven process with state-of-the art methodology supported by the American College of Rheumatology and the European League Against Rheumatism led to publication of new gout classification criteria.

Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71(11):1765–70. doi:10.1136/annrheumdis-2012-201687.CrossRefPubMed

Perez-Ruiz F, Urionaguena I, Carmona-Ortells L. Epidemiology and health-related services. Curr Opin Rheumatol. 2016;28(2):104–9. doi:10.1097/BOR.0000000000000258.CrossRefPubMed

Clarson LE, Chandratre P, Hider SL, Belcher J, Heneghan C, Roddy E, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22(3):335–43. doi:10.1177/2047487313514895.CrossRefPubMedPubMedCentral

Liu SC, Xia L, Zhang J, Lu XH, Hu DK, Zhang HT, et al. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS One. 2015;10(7), e0134088. doi:10.1371/journal.pone.0134088.CrossRefPubMedPubMedCentral

Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895–900.CrossRefPubMed

Gout. In: Kellgren JH, Jeffery MR, Ball JF, editors. The epidemiology of chronic rheumatism. Vol. I. Oxford: Blackwell Scientific; 1963. p. 327.

Decker JL. Report from the subcommittee on diagnostic criteria for gout. In: Bennett PH, Wood PHN, editors. Population studies of the rheumatic diseases. Proceedings of the Third International Symposium. New York: Amsterdam: Excerpta Medica Foundation; 1968; 1966. p. 385–7.

8.••

Dalbeth N, Fransen J, Jansen TL, Neogi T, Schumacher HR, Taylor WJ. New classification criteria for gout: a framework for progress. Rheumatology (Oxford). 2013;52(10):1748–53. doi:10.1093/rheumatology/ket154. This paper discusses in details the rationale for developing new and validated classification criteria for gout.CrossRef

9.••

Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67(10):2557–68. doi:10.1002/art.39254. The jointly published 2015 ACR-EULAR Gout Classification Criteria.CrossRefPubMed

10.••

Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74:1789–98. doi:10.1136/annrheumdis-2015-208237. The jointly published 2015 ACR-EULAR Gout Classification Criteria.CrossRefPubMedPubMedCentral

11.•

Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res. 2015;67(7):891–7. doi:10.1002/acr.22583. Reviews the differences between classification criteria and diagnosis.CrossRef

12.•

Taylor WJ, Fransen J. Distinctions between diagnostic and classification criteria: comment on the article by Aggarwal et al. Arthritis Care Res. 2016;68(1):149–50. doi:10.1002/acr.22671. Reviews the differences between classification criteria and diagnosis.CrossRef

13.

Pelaez-Ballestas I, Hernandez Cuevas C, Burgos-Vargas R, Hernandez Roque L, Teran L, Espinoza J, et al. Diagnosis of chronic gout: evaluating the american college of rheumatology proposal, European league against rheumatism recommendations, and clinical judgment. J Rheumatol. 2010;37(8):1743–8. doi:10.3899/jrheum.091385.CrossRefPubMed

14.

Janssens HJ, Fransen J, van de Lisdonk EH, van Riel PL, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010;170(13):1120–6. doi:10.1001/archinternmed.2010.196.CrossRefPubMed

15.

Taylor WJ, Fransen J, Dalbeth N, Neogi T, Schumacher HR, Brown M, et al. Performance of classification criteria for gout in early and established disease. Ann Rheum Dis. 2016;75(1):178–82. doi:10.1136/annrheumdis-2014-206364.CrossRefPubMed

16.

Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol. 2009;15(1):22–4. doi:10.1097/RHU.0b013e3181945b79.CrossRefPubMed

17.

Nakayama DA, Barthelemy C, Carrera G, Lightfoot Jr RW, Wortmann RL. Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum. 1984;27(4):468–71.CrossRefPubMed

18.

Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–62. doi:10.1038/nrrheum.2015.91.CrossRefPubMed

19.

Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136–41. doi:10.1002/art.30520.CrossRefPubMed

20.

Centers for Disease Control and Prevention. The Third National Health and Nutrition Examination Survey (NHANES III 1988–94) reference manuals and reports [CD-ROM]. Hyattsville (MD): National Center for Health Statistics. 1996.

21.

Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661–7. doi:10.1136/annrheumdis-2013-204463.CrossRefPubMed

22.

Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis. 1997;56(1):22–6.CrossRefPubMedPubMedCentral

23.

Winnard D, Wright C, Taylor WJ, Jackson G, Te Karu L, Gow PJ, et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology (Oxford). 2012;51(5):901–9. doi:10.1093/rheumatology/ker361.CrossRef

24.

Stamp LK, Wells JE, Pitama S, Faatoese A, Doughty RN, Whalley G, et al. Hyperuricaemia and gout in New Zealand rural and urban Maori and non-Maori communities. Intern Med J. 2013;43(6):678–84. doi:10.1111/imj.12062.CrossRefPubMed

25.

Wijnands JM, Viechtbauer W, Thevissen K, Arts IC, Dagnelie PC, Stehouwer CD, et al. Determinants of the prevalence of gout in the general population: a systematic review and meta-regression. Eur J Epidemiol. 2015;30(1):19–33. doi:10.1007/s10654-014-9927-y.CrossRefPubMed

26.

Karis E, Crittenden DB, Pillinger MH. Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street. South Med J. 2014;107(4):235–41. doi:10.1097/SMJ.0000000000000082.CrossRefPubMed

27.

Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125(7):679–87 e1. doi:10.1016/j.amjmed.2011.09.033.CrossRefPubMed

28.

Scire CA, Manara M, Cimmino MA, Govoni M, Salaffi F, Punzi L, et al. Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther. 2013;15(5):R101. doi:10.1186/ar4281.CrossRefPubMedPubMedCentral

29.

Shields GE, Beard SM. A Systematic Review of the Economic and Humanistic Burden of Gout. Pharmacoeconomics. 2015;33(10):1029–47. doi:10.1007/s40273-015-0288-5.CrossRefPubMed

30.

Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD. Health-related quality of life in gout: a systematic review. Rheumatology (Oxford). 2013;52(11):2031–40. doi:10.1093/rheumatology/ket265.CrossRef

31.

Han GM, Michaud K, Yu F, Watanabe-Galloway S, Mikuls TR. The increasing public health burden of arthritis, other rheumatic conditions, and comorbidity: results from a statewide health surveillance system, 2007 to 2012. Arthritis Care Res. 2016. doi:10.1002/acr.22856.

32.

Robinson PC, Merriman TR, Herbison P, Highton J. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999-2009. Rheumatology (Oxford). 2013;52(1):118–26. doi:10.1093/rheumatology/kes253.CrossRef

33.

Neogi T. Clinical practice. Gout. N Engl J Med. 2011;364(5):443–52. doi:10.1056/NEJMcp1001124.CrossRefPubMed

34.

Robinson PC, Dalbeth N. Advances in pharmacotherapy for the treatment of gout. Expert Opin Pharmacother. 2015;16(4):533–46. doi:10.1517/14656566.2015.997213.CrossRefPubMed

35.

Dumusc A, So A. Interleukin-1 as a therapeutic target in gout. Curr Opin Rheumatol. 2015;27(2):156–63. doi:10.1097/BOR.0000000000000143.CrossRefPubMed

36.

Durcan L, Grainger R, Keen HI, Taylor WJ, Dalbeth N. Imaging as a potential outcome measure in gout studies: a systematic literature review. Semin Arthritis Rheum. 2015. doi:10.1016/j.semarthrit.2015.09.008.

37.

Glazebrook KN, Guimaraes LS, Murthy NS, Black DF, Bongartz T, Manek NJ, et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. Radiology. 2011;261(2):516–24. doi:10.1148/radiol.11102485.CrossRefPubMed

38.

McQueen FM, Doyle A, Dalbeth N. Imaging in gout--what can we learn from MRI, CT, DECT and US? Arthritis Res Ther. 2011;13(6):246. doi:10.1186/ar3489.CrossRefPubMedPubMedCentral

39.•

Ogdie A, Taylor WJ, Weatherall M, Fransen J, Jansen TL, Neogi T, et al. Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Ann Rheum Dis. 2015;74(10):1868–74. doi:10.1136/annrheumdis-2014-205431. Represents some of the work performed during the development of the 2015 ACR-EULAR Gout Classification Criteria.CrossRefPubMed

40.

Taylor WJ, Fransen J, Dalbeth N, Neogi T, Ralph Schumacher H, Brown M, et al. Diagnostic Arthrocentesis for Suspicion of Gout Is Safe and Well Tolerated. J Rheumatol. 2016;43(1):150–3. doi:10.3899/jrheum.150684.CrossRefPubMed

41.

Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis. 2007;66(10):1311–5. doi:10.1136/ard.2007.070755.CrossRefPubMedPubMedCentral

42.

Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350(11):1093–103. doi:10.1056/NEJMoa035700.CrossRefPubMed

43.•

Prowse RL, Dalbeth N, Kavanaugh A, Adebajo AO, Gaffo AL, Terkeltaub R, et al. A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol. 2013;40(4):498–505. doi:10.3899/jrheum.121037. Represents some of the work performed during the development of the 2015 ACR-EULAR Gout Classification Criteria.CrossRefPubMed

44.•

Taylor WJ, Fransen J, Jansen TL, Dalbeth N, Schumacher HR, Brown M, et al. Study for Updated Gout Classification Criteria: identification of features to classify gout. Arthritis Care Res. 2015;67(9):1304–15. doi:10.1002/acr.22585. Represents some of the work performed during the development of the 2015 ACR-EULAR Gout Classification Criteria.CrossRef

45.

Berendsen D, Jansen TL, Taylor W, Neogi T, Fransen J, Pascual E, et al. A critical appraisal of the competence of crystal identification by rheumatologists [abstract]. Ann Rheum Dis. 2013;72 Suppl 3:A981–2. doi:10.1136/annrheumdis-2013-eular.2951.CrossRef

46.•

Hansen P, Ombler F. A new method for scoring additive multi-attribute value models using pairwise rankings of alternatives. J Multi-Criteria Decis Anal. 2008;15(3-4):87–107. Outlines the theory behind the conjoint analytic methodology used in the development of several recent classification criteria efforts by the ACR and EULAR.CrossRef

47.•

Taylor WJ. Pros and cons of conjoint analysis of discrete choice experiments to define classification and response criteria in rheumatology. Curr Opin Rheumatol. 2016;28(2):117–21. doi:10.1097/BOR.0000000000000259. Provides a review of the experience in using discrete choice experiments in various applications of relevance to rheumatology, including the 2015 ACR-EULAR Gout Classification Criteria.CrossRefPubMed

48.

Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal R, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: phase 2 methodological report. Arthritis Rheum. 2010;62(9):2582–91. doi:10.1002/art.27580.CrossRefPubMedPubMedCentral

49.

Johnson SR, Naden RP, Fransen J, van den Hoogen F, Pope JE, Baron M, et al. Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. J Clin Epidemiol. 2014;67(6):706–14. doi:10.1016/j.jclinepi.2013.12.009.CrossRefPubMedPubMedCentral

50.

June RR, Aggarwal R. The use and abuse of diagnostic/classification criteria. Best Pract Res Clin Rheumatol. 2014;28(6):921–34. doi:10.1016/j.berh.2015.04.004.CrossRefPubMed

Title: Gout Classification Criteria: Update and Implications
Authors: Ana Beatriz Vargas-Santos
William J. Taylor
Tuhina Neogi
Publication date: 01-07-2016
Publisher: Springer US
Published in: Current Rheumatology Reports / Issue 7/2016
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-016-0594-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2016

Incentives in Rheumatology: the Potential Contribution of Physician Responses to Financial Incentives, Public Reporting, and Treatment Guidelines to Health Care Sustainability

Erratum to: The Role of Sirtuins in Cartilage Homeostasis and Osteoarthritis

The Role of Sirtuins in Cartilage Homeostasis and Osteoarthritis

Biological Therapy-Induced Systemic Vasculitis

Biologics in Pediatric Rheumatology: Quo Vadis?

Stress Dose Steroids: Myths and Perioperative Medicine

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage